Oilon: Finnish Heat Pump Expertise Appraised as the Best in Europe
The Finnish energy technology company Oilon and energy company Helen have won the respected The Heat Pump Award in the DecarBuilding series with their mutually developed heat pump solution. The competition, arranged by the European Heat Pump Association EHPA since 2011, rewards most innovative and energy-efficient heat pump projects on the continent. The award was given in Brussels on Wednesday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005541/en/
Sales Manager Heli Liedes, Sales, Marketing Director Sami Pekkola and Chief Business Officer Martti Kukkola received the award in Brussels on Wednesday. (Photo: Business Wire)
The award was given for an apartment building built in the Finnish capital city of Helsinki, where a new type of heat pump solution was implemented. The heat pump is used to heat and cool down the building. The heat sources are the building’s waste water, the waste heat generated by the refrigerators and cooling systems of a food market located in the building, and geothermal heat. Additionally, when the amount of heat generated exceeds the consumption in the building, it will be supplied into the Helen network as district heat.
– Not a single joule of energy is wasted here, says Oilon Chief Business Officer Martti Kukkola.
– Even the energy generated by flushing the toilet is used.
The unique concept, born in partnership between the energy companies, has taken the energy efficiency and environmentalism of new construction projects to another level. It is a result of patient product development efforts done by Oilon in terms of heat pump technology and by Oilon and Helen together in terms of waste heat recovery.
The goal of two-way energy generation and use is to achieve full carbon neutrality in the production of heat and cooling. Heat pumps have a large role to play here.
– Many different means are needed on the road to carbon neutrality and energy independence, among which powerful heat pumps are some of the best, says Kukkola.
An intelligently reacting Oilon ChillHeat pump is the beating heart of the circular economy hybrid solution rewarded on Wednesday in Brussels as well, which is able to operate in different part load and temperature ranges.
– The most innovative aspect is that various heat sources can be utilised at different times of the year together at an optimal and carbon-neutral way, Kukkola explains.
Both Oilon and Helen appreciate the award as a recognition of their partnership and of the extremely topical issue of the development of energy efficiency.
– Investing in technologies that utilise energy efficiency and waste heat is now important than ever, says Senior Vice President Sari Mannonen of Helen’s Solutions and Portfolio Department, expressing gratitude:
– This recognition is also another indication of how partnerships between enterprises can create novel innovations and technologies in order to achieve energy independence, Mannonen says.
Attachments
Image: Oilon’s high-power heat pump
Image: EHPA awards gala in Brussels, 28 September 2022
Oilon
Oilon is a family-owned, global energy and environmental technology company, founded in 1961. Oilon specialises in energy and environmental technology with focus on industrial heat pumps and chillers, ground source heat pumps, and burners and combustion systems. Oilon conducts continuous product development to improve energy efficiency, reduce emissions and create solutions based on renewable energy sources.
Oilon has a of €70 million turnover and employs 380 people. The company has production facilities in Finland, the United States and China, as well as sales offices in Brazil and Germany. Furthermore, Oilon runs an international sales network of 70 dealers.
Helen Ltd
Helen Ltd helps to make everyday life a little easier for over 550,000 customers in Finland. In addition to heat, cooling and electricity, we offer solutions for regional and renewable energy, smart buildings and electric transport. We are developing a smarter, carbon-neutral energy system that enables everyone to produce, use and save energy with respect for the environment. We aim to achieve 100% carbon neutrality in our energy production by 2030. Let’s join forces and turn the opportunities of a new energy era into reality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005541/en/
Contact information
More information
Martti Kukkola, Chief Business Officer
martti.kukkola@oilon.com
+358 400312060
Sari Mannonen, Senior Vice President of the Solutions and Portfolio Department, Helen
sari.mannonen@helen.fi
+358 452651345
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom